Brief: Aridis Closes Patient Enrollment In Phase 2A Study Of Ar-501 In Cystic Fibrosis
30/11/2022 12:30
Nov 30 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS ANNOUNCES A KEY MILESTONE OF CLOSING OF PATIENT
ENROLLMENT IN THE PHASE 2A STUDY OF AR-501 IN CYSTIC FIBROSIS
PATIENTS
* ARIDIS PHARMACEUTICALS INC - ON TRACK TO COMPLETE DATABASE
LOCK,
DATA ANALYSES, AND DISCLOSE TOP-LINE DATA IN Q1 OF 2023
Source text for Eikon: ID:nGNX9Q05yZ
Further company coverage: ARDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music